Streptokinase of heparin in the treatment of XXXX . Follow-up results of a prospective study.

@entity1 @entity1150
In a previous study on 42 @entity1 with acute @entity1150 , randomly allocated to treatment with streptokinase or heparin, we found that 71.4% of the streptokinase-treated @entity1 achieved phlebographically significant thrombolysis as compared to 23.8% in the heparin group. These @entity1 have been reevaluated after a mean observation period of 6 1/2 years. Seven @entity1 had died and there were no other drop-outs. Thus, 35 @entity1 were subjected to the follow-up study consisting of phlebography and clinical examination. The evaluations were performed without knowledge of the initial therapy. Seven @entity1 had phlebographically normal veins, and all belonged to the streptokinase group. This difference between the treatment groups is statistically highly significant (p less than 0.01). At clinical examination, 13 of the 17 @entity1 in the streptokinase group had normal legs and 4 exhibited moderate postthrombotic changes. In contrast, 3 of the heparin-treated @entity1 showed serious postthrombotic changes with open leg ulcers, and only 6 of 18 @entity1 in this group had normal legs. The present results strongly support the assumption that streptokinase therapy is the best treatment at present in @entity1 with acute @entity1150 . This has been shown for the initial thrombolysis, and now also for the avoidance of late postthrombotic changes.
